CSL Seqirus

FLUCELVAX® (Influenza Vaccine) Coding and Billing

As a cell-based influenza vaccine, FLUCELVAX has a unique Current Procedural Terminology (CPT) code.

Code for the FLUCELVAX vaccine administered

2025-2026 NDC Carton[1]	2025-2026 NDC Unit-of-Use[1]	Presentation[1]	Product Billing CPT Code[2]	Description[1]	CVX Code*[2]	MVX Code
70461-655-03	70461-655-04	0.5-mL pre-filled syringe	90661	Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5-mL dosage, for intramuscular use	153	SEQ

*CVX=vaccine administered code indicates which product was used and is used in combination with the manufacturer (MVX) code.
NDC=National Drug Code
Note: Some payers may require use of NDCs. If so, determine if the payer requires the carton NDC or the unit-of-use NDC, and then determine if the payer requires the 10-digit or 11-digit format. If 11-digit, add a leading zero to the middle section of numbers.

Code for the administration of FLUCELVAX

Report the appropriate administration code in addition to the CPT code for FLUCELVAX.[2]
Note: Medicare (and some other payers) requires use of the Healthcare Common Procedure Coding System (HCPCS) code, G0008, for administration of preventive vaccines, including influenza, regardless of age. Other payers use the appropriate CPT code based on age and counseling provided.[3]

Include the appropriate *International Classification of Diseases, Tenth Revision* (ICD-10) diagnosis code

Report the ICD-10 diagnosis code, Z23, indicating an encounter for vaccine administration. The ICD-10 diagnosis code should be linked to both the vaccine and the administration code.[3]

Determine if modifier 25 is appropriate

When FLUCELVAX is administered on the same date as a significant and separately identifiable Evaluation and Management (E/M) visit, apply modifier 25 to the E/M CPT code, denoting a "significant and separately identifiable" service from the vaccine and vaccine administration service.[4]

CPT Code[5]	Description
90460	Immunization administration through 18 years of age (via any route of administration) with counseling by physician or other qualified healthcare professional; first or only component of each vaccine or toxoid administered
90461 (add-on code)	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified healthcare professional; each additional vaccine or toxoid component administered (list separately in addition to code for primary procedure)
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) NOTE: Report this code for immunization administration of any vaccine that is not accompanied by face-to-face physician or other qualified healthcare professional counseling the patient and/or family, or for patients over 18 years of age.
HCPCS Code[3]	**Description**
G0008	Seasonal influenza virus vaccine administration
ICD-10 Code[3]	**Description**
Z23	Encounter for immunization

Visit FLUCELVAX.com for additional resources and information.

Please see Important Safety Information on next page, and the full US Prescribing Information for FLUCELVAX.

For US Healthcare Professional Use Only
This information does not constitute a guarantee or warranty of coverage benefits or reimbursement.

Questions?

Call CSL Seqirus Customer Service
(855) 358-8966, option 2

FLUCELVAX® (Influenza Vaccine)
INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

FLUCELVAX is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUCELVAX is approved for use in persons 6 months of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Do not administer FLUCELVAX to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine.

WARNINGS AND PRECAUTIONS

If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUCELVAX should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUCELVAX.

Syncope (fainting) has been reported following vaccination with FLUCELVAX. Procedures should be in place to avoid injury from fainting.

After vaccination with FLUCELVAX, immunocompromised individuals, including those receiving immunosuppressive therapy, may have a reduced immune response.

Vaccination with FLUCELVAX may not protect all vaccine recipients against influenza disease.

ADVERSE REACTIONS

Data for FLUCELVAX QUADRIVALENT are relevant to FLUCELVAX because both vaccines are manufactured using the same process and have overlapping compositions.

In children 6 months through 3 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were tenderness (28%), erythema (26%), induration (17%) and ecchymosis (11%). The most common systemic adverse reactions were irritability (28%), sleepiness (27%), diarrhea (18%) and change of eating habits (17%).

In children 4 through 8 years of age who received FLUCELVAX, the most commonly reported local injection-site adverse reactions were pain (29%) and erythema (11%). The most common systemic adverse reaction was fatigue (10%).

In children and adolescents 9 through 17 years of age who received FLUCELVAX, the most commonly reported injection-site adverse reactions were pain (34%) and erythema (14%). The most common systemic adverse reactions were myalgia (15%) and headache (14%).

In adults 18 through 64 years of age who received FLUCELVAX, the most commonly reported injection-site adverse reactions were pain (28%) and erythema (13%). The most common systemic adverse reactions were headache (16%), fatigue (12%), myalgia (11%) and malaise (10%).

In adults ≥65 years who received FLUCELVAX the most commonly reported injection-site reaction was erythema (10%). The most common systemic adverse reactions were fatigue (11%), headache (10%) and malaise (10%).

Other adverse events may occur.

To report SUSPECTED ADVERSE REACTIONS, contact CSL Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Before administration, please see the full US Prescribing Information for FLUCELVAX.

Information on reimbursement is provided as a courtesy. Due to the rapidly changing nature of the law, Medicare payment policy, and/or reliance on information provided by outside sources, the information provided herein does not constitute a guarantee or warranty that reimbursement will be received or that the codes identified herein are or will remain applicable. This information is provided "as is" and without any other warranty or guarantee, expressed or implied, as to completeness or accuracy, or otherwise.

Providers must confirm or clarify coding and coverage from their respective payers, and are responsible for accurate reporting of products in accordance with particular payer requirements.

References: 1. FLUCELVAX. Package insert. Seqirus Inc. **2.** Centers for Disease Control and Prevention. CPT codes mapped to CVX codes. Accessed May 5, 2025. https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cpt **3.** Centers for Medicare & Medicaid Services. Flu shot & administration. Accessed May 5, 2025. https://www.cms.gov/Medicare/Prevention/PrevntionGenInfo/medicare-preventive-services/MPS-QuickReferenceChart-1.html#FLU **4.**. American Medical Association. Current Procedural Terminology 2025 (Professional Edition). American Medical Association; 2024. **5.** American Academy of Pediatrics. Coding for pediatric preventive care 2025. Accessed May 5, 2025. https://downloads.aap.org/AAP/PDF/Coding%20Preventive%20Care.pdf